[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 sale 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
검색광고안내
과학기술용어에 대한 과기인 인식조사
스폰서배너광고 안내  배너1 배너2 배너3 배너4
과학으로 본 코로나19 (COVID-19)
전체보기 한빛사논문 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
안명주 (Myung-Ju Ahn)
성균관대학교 의과대학
CV PDF 792 KB
관련인물
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Ann. Oncol., Available online 5 July 2020 | https://doi.org/10.1016/j.annonc.2020.06.017
Cancer Biology/Oncology ( 2020-07-06 )  | 
한빛사논문
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
J. Thorac. Oncol., Volume 11, Issue 4, Supplement, April 2016, Page S115 | https://doi.org/10.1016/S1556-0864(16)30246-5
( 2020-06-08 )  | 
상위피인용논문
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
Nat. Commun., Published: 08 May 2020 11, Article number: 2285 (2020) | https://doi.org/10.1038/s41467-020-16164-1
Bioinformatics, Cancer Biology/Oncology, Genomics ( 2020-05-11 )  | 
한빛사논문
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
J. Clin. Oncol., Published online : December 06, 2019 | DOI: 10.1200/JCO.19.00457
Cancer Biology/Oncology ( 2019-12-13 )  | 
한빛사논문
  
Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
J. Clin. Oncol., Published online : December 11, 2019 | DOI: 10.1200/JCO.19.00931
Cancer Biology/Oncology ( 2019-12-13 )  | 
한빛사논문
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Lancet Oncol., Available online 3 October 2019 | https://doi.org/10.1016/S1470-2045(19)30504-2
Cancer Biology/Oncology ( 2019-10-04 )  | 
한빛사논문
The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors
Clin. Cancer Res., Published Online First January 15, 2019 | doi: 10.1158/1078-0432.CCR-18-1449
Cancer Biology/Oncology ( 2019-01-17 )  | 
한빛사논문
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
J. Clin. Oncol., Published online before print June 15, 2018 | https://doi.org/10.1200/JCO.2017.77.3184
Cancer Biology/Oncology ( 2018-06-19 )  | 
한빛사논문
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Lancet Resp. Med., Volume 5, Issue 11, November 2017, Pages 891-902 | https://doi.org/10.1016/S2213-2600(17)30378-8
Medicine ( 2017-11-08 )  | 
한빛사논문
    댓글 1
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
J. Clin. Oncol., 35, no. 23 (August 2017) 2613-2618. | DOI: http://dx.doi.org/10.1200/JCO.2016.71.3701
Cancer Biology/Oncology ( 2017-05-22 )  | 
한빛사논문
처음 이전  1 02  다음 끝
(주)비아이코퍼레이션
한빛사 안내
한빛사 운영안내
선정저널 목록
최근 3년간 3회 이상 등록 연구자
한빛사논문 결산자료
한빛사 통계
국내 바이오분야 연구성과 Top5
한빛사논문 등록하기 >
연구자정보업데이트 신청하기
최신댓글
전수영(Gastroenterology) 댓글 4
김인규(Cell Death Differ.) 댓글 1
양진성(Nat. Commun.) 댓글 1
이주현(Cell Stem Cell) 댓글 1
최진욱(Cell Stem Cell) 댓글 4
서영진(J. Clin. Invest.) 댓글 1
한미선(JAMA Pediatr.) 댓글 1
송인선(Science) 댓글 1
신동혁(Nature) 댓글 1
조효제(Nat. Chem. Biol.) 댓글 3
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
에펜도르프코리아 광고